General Genetics Corporation (GGC) announces a new pharmacogenomic testing study that investigates the frequency of adverse drug effects on a select population with known genetic variations that affect drug metabolic pathways, to determine if pharmacogenomic testing can ameliorate risks.(PRWeb March 19, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11663760.htm
